亚洲国产成人精品女人久久久-亚洲女人被黑人巨大进入-亚洲爆乳无码一区二区三区-亚洲视频在线观看,狠狠淫

10月24日，中草藥雜志社組織召開了2023年4刊編委會，在遵循公平、公正、公開原則的基礎上，結合發表論文在數據庫中引用和下載情況，經過專家評審嚴格篩選，評選出了2020-2023 年發表在雜志社4刊上的優秀論文10篇。

獲得 2020-2023 年中草藥雜志社優秀論文獎的10篇論文是：

Chinese Herbal Medicines（CHM ）4篇：

①  題目：Pay attention to situation of SARS-CoV-2 and TCM advantages in treatment of novel

作者：Changxiao Liu（劉昌孝，天津藥物研究院）

摘要：Since the outbreak of the new coronavirus epidemic, novel coronavirus has infected nearly 100,000 people in more than 110 countries. How to face this new coronavirus epidemic outbreak is an important issue. Basic reproduction number (R0) is an important parameter in epidemiology; The basic reproduction number of an infection can be thought of as the expected number of cases directly generated by one case in a population where all individuals are susceptible to infection. Epidemiology dynamics is a mathematical model based on a susceptibility-infection-recovery epidemic model. Researchers analyzed the epidemiological benefits of different transmission rates for the establishment of effective strategy in prevention and control strategies for epidemic infectious diseases. In this review, the early use of TCM for light and ordinary patients, can rapidly improve symptoms, shorten hospitalization days and reduce severe cases transformed from light and normal. Many TCM formulas and products have wide application in treating infectious and non-infectious diseases. The TCM theoretical system of treating epidemic diseases with TCM and the treatment scheme of integrated Chinese and Western medicine have proved their effectiveness in clinical practice. TCM can cure COVID-19 pneumonia, and also shows that the role of TCM in blocking the progress of COVID-19 pneumonia.

作者簡介：

劉昌孝 院士

中國工程院院士、研究員、博士研究生導師。現任天津藥物研究院名譽院長、終身首席科學家和學術委員會主任，中國-東盟傳統藥物國際合作聯合實驗室主任，國務院發展研究中心健康中國促進網中醫藥院士專家中心主任、國家科技獎勵評審專家、國家藥監局中藥監管科學研究中心專家委員會主任、中國藥典委員會顧問、中國藥學會常務理事、中國醫學科學院學部委員、中國中醫科學院學部委員和執行委員、國際藥物代謝研究會中國辦事處主任、國家藥品監督管理局仿制藥一致性評價專家委員會副主任、天津市藥學會會長、天津市藥品監管科學研究會理事長、天津市學會學研究會名譽理事長。

劉昌孝是我國藥代動力學的學科開拓者和學科帶頭人之一，從事藥理學、藥代動力學、現代中藥和中藥質量研究50余年，致力于生物醫藥發展戰略研究，承擔和參與多項生物醫藥戰略咨詢研究項目。承擔過包括國家“973”和“863”項目、國家科技部國際合作項目、國家重大專項課題、國家自然科學基金重點項目等國家重大研究項目50余項，發表論文600多篇，在國內外出版中英文學術專著38部。曾獲得國務院特殊津貼(1992)，香港紫金花醫學成就獎（2000），香港紫荊花醫學創新金獎（2000），天津市勞動模范（2000），全國勞動模范（2005），全國優秀科技工作者（2012），國際藥物代謝研究會“特別貢獻獎（2013），天津市濱海科技突出成就獎（2016），中國藥學會突出貢獻獎（2017），世界中醫藥聯合會中藥分析與標準“終身成就獎”（2018），循證中醫藥研究“終身成就獎”（2020）、“卓越貢獻獎”（2021），光華工程科技特別貢獻獎（醫藥衛生學部全體院士，2020），中國藥學會“最美科技工作者”稱號（2021），國家科技進步獎二等獎（第一完成人，2020）。

②  題目：Phytochemicals and antioxidant activity of alcoholic/hydroalcoholic extract of Trifolium pratense

作者： Mohsen Akbaribazm, Mohammad Rasoul Khazaei, Mozafar Khazaei（伊朗克爾曼沙赫醫科大學）

摘要：Objective: Trifolium pratense has many healing properties, including fewer complications of menopause, cancer cell suppression, reducing blood glucose and lipids, as well as cardiovascular beneficial effects. The purpose of this study was to identify the phytochemical and mineral composition of T. pratense. Methods: Plant aerial parts were harvested and dried, and then hydroalcoholic and alcoholic extracts were prepared. Gas chromatography–mass spectrometry (GC-MS) analytical method was used to identify volatile compounds then liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS) was used to identify polyphenols and the mineral elements were identify by inductively coupled plasma atomic emission spectrometer/ICP-AES and scanning electron microscope-energy-dispersive X-ray spectroscopy (SEM-EDS) methods. Total phenolic content (TPC) was determined based on colorimetric method, and total flavonoid content (TFC) was established based on the folin-chiocalteau reagent. Furthermore, two assays (DPPH and FRAP) were used to measure the antioxidant capacity of T. pratense ethanolic extract. Results: A total of 37 polyphenol and 107 peaks were identified by LC-ESI-MS analysis, and the GC/MS method also detected 21 volatile compounds, the most important of which were methylcyclopentane, dimethylpentanal and hexadecanol. A total of 18 mineral elements, including K, Mg, Al, Si, Zn, Ni, Cu, Se, Co, Fe, Mn, and Ca in the plant, were identified ICP-AES and SEM-EDS analysis. Conclusion: T. pratense has many therapeutic compounds such as polyphenol (isoflavone and flavonoids), volatile compounds, and essential mineral elements, which can be formulated purely and used in the pharmaceutical and traditional medicine industries.

作者簡介：

Prof. Mozafar Khazaei (Ph.D., M.Sc, B.Sc)

Head of Fertility and Infertility Research Center and Tissue Engineering Dep. in Medical School of Kermanshah University of Medical Sciences, with research interests in Histology, Tissue Engineering, Reproductive Biology, Cancer Biology, Diabetes and Herbal Medicine.

③  題目：In vitro and in silico anti-oxidant, cytotoxicity and biological activities of Ficus benghalensis

作者： Pukar Khanal, Basanagouda M. Patil（印度KLE高等教育研究院）

摘要：Objective: To report in vitro anti-oxidant activity and cytotoxicity of hydroalcoholic extract of Ficus benghalensis (bark) and Duranta repens(whole plant), and present the probable biological spectrum of major anti-oxidants from both plants. Methods: The coarse powder of both plants was first extracted with 70% ethanol (maceration) and followed by 99% ethanol (Soxhlet-extraction). Anti-oxidant activity of the extracts was evaluated by using DPPH, H2O2, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS), NO scavenging assay, total antioxidant capacity, cupric reducing antioxidant capacity (CUPRAC), and metal chelating assay. Cytotoxicity of both extracts was evaluated by using MTT assay in both tumor and normal cell lines i.e. Chinese hamster ovary cells (CHO) and A549 cells. Biological activity of individual anti-oxidant compounds was identified by using prediction of activity spectra for substances and a docking study was performed by using autodock4.0. Results: Hydroalcoholic extract of F. benghalensis and D. repens showed the highest free radical scavenging capacity (ABTS) and chelating capacity respectively. Both extracts showed minimum cytotoxicity in normal cell lines compared to tumor cell lines. Computer imitation hits reflected the multiple biological activities agreeing with the folk use and some scientific reports. Further, we found the potent binding affinity of predicted anti-oxidant compounds with multiple protein molecules involved in oxidative stress. Conclusion: The present study reports the probable anti-oxidant mechanism for two folk agents and also presents probable pharmacological activities via computer simulations.

作者簡介：

Dr. Pukar Khanal, Ph.D.

Dr. Pukar Khanal, Ph.D., was a university gold medalist in his undergraduate and postgraduate studies in the faculty of pharmaceutical science at the KLE Academy of Higher Education and Research, Belagavi, India. Dr. Khanal focuses on cross-linking brain glucotoxicity and/or insulin resistance with compromised neuronal signaling as a potential risk of developing cognitive impairment. He further attempts to identify novel disease-modifying interventions from the existing pool of small molecules against endocrine disturbances, neurological disorders, and cancer using both computational and experimental approaches, including the impact of psychotropic molecules in normal physiology. He seeks an approach to linking missing dots (manipulated biological spectra, cellular processes, immune regulation, and molecular function) in complex polygenic and rare diseases using a series of computational approaches followed by wet-lab experiments (in vitro studies including zebrafish and rodent models). Dr. Khanal extensively investigates the multitarget selectivity of small molecules from a deep compound pool to identify novel therapeutic applications through chemical fingerprinting. He believes this approach may neutralize the complex network of polygenic conditions, e.g., manipulated glucose metabolism (type 2 diabetes mellitus), altered neuronal signaling, and cognitive impairment (Alzheimer’s disease). Further, he sought to establish Danio rerio as a preliminary animal model for olanzapine-induced metabolic changes by assessing manipulated metabolic rate and compromised lipid metabolism.

Prof. Dr. B. M. Patil

Prof. Patil is currently affiliated with PRES’s Pravara Rural College of Pharmacy in Pravaranagar, Loni, Maharashtra, India, as the Professor and Director. Previously, he was affiliated as the Professor, Principal, and Dean of the Faculty of Pharmacy at KLE Academy of Higher Education and Research, Belagavi, India, and supervised doctorate and postgraduate students in their research. His research interests cover the pathophysiology of insulin resistance-induced endothelial dysfunction, cancer pharmacology, and neuropharmacology (Alzheimer’s and Parkinson’s disease). His expertise in experimental pharmacology includes ex vivo (isolated tissue experiments), in vitro (enzyme inhibition against postprandial hyperglycemia), and in vivo pharmacology. One of his key research interests is to identify a novel approach to addressing metabolic disturbances (mild hyperglycemia, hypertension, and weight gain) in olanzapine therapy. He uses computational pharmacology and its experimental validation to identify the multiple secondary metabolites in traditional medicines against various diseases. He uses computational pharmacology to screen the possible active ingredients from ethnobotanicals and observe the possible effects in vivo. He was awarded the “Prof. M.L. Khorana Memorial Award” for publishing the best research paper in the Indian Journal of Pharmaceutical Sciences. Further, he proposed that Danio rerio could be one of the preliminary animal models for olanzapine-induced weight gain.

④  題目：Pharmaceutical resource discovery from traditional medicinal plants

作者：Hao Da-cheng，Xiao Pei-gen（郝大程， 肖培根，大連交通大學）

摘要：The worldwide botanical and medicinal culture diversity are astonishing and constitute a Pierian spring for innovative drug R&D. Here, the latest awareness and the perspectives of pharmacophylogeny and pharmacophylogenomics, as well as their expanding utility in botanical drug R&D, are systematically summarized and highlighted. Chemotaxonomy is based on the fact that closely related plants contain the same or similar chemical profiles. Correspondingly, it is better to combine morphological characters, DNA markers and chemical markers in the inference of medicinal plant phylogeny. Medicinal plants within the same phylogenetic groups may have the same or similar therapeutic effects, thus forming the core of pharmacophylogeny. Here we systematically review and comment on the versatile applications of pharmacophylogeny in 1) looking for domestic resources of imported drugs, 2) expanding medicinal plant resources, 3) quality control, identification and expansion of herbal medicines, 4) predicting the chemical constituents or active ingredients of herbal medicine and assisting in the identification and determination of chemical constituents, 5) the search for new drugs sorting out, and 6) summarizing and improving herbal medicine experiences, etc. Such studies should be enhanced within the context of deeper investigations of molecular biology and genomics of traditional medicinal plants, phytometabolites and metabolomics, and ethnomedicine-based pharmacological activity, thus enabling the sustainable conservation and utilization of traditional medicinal resources.

作者簡介：

郝大程 教授

大連交通大學教授，一直從事藥用植物和植物藥資源環境相關研究，已發表SCI論文近百篇，出版中文學術專著1部和英文學術專著3部，獲得2020年中華中醫藥學會科學技術獎一等獎（3/11），授權發明專利兩項，實用新型專利兩項，獲得國家級及省部級研究資助多項。擔任4種SCI期刊編委和2種核心刊編委。

《中草藥》4篇：

⑤  題目：丹參化學成分及其藥理作用研究進展

作者：萬新煥，王立柱（山東中醫藥大學）

摘要：丹參Salvia miltiorrhiza是一味臨床常用的具有活血化瘀功效的中藥。丹參有著廣泛的藥理作用，臨床主要用于月經不調、心悸失眠及各種心血管疾病，尤其是心絞痛和心肌梗死等疾病的治療。丹參化學成分是其發揮藥理作用的重要物質基礎，綜述了丹參化學成分及其藥理作用的國內外研究進展，分析丹參研究現狀及研究方向，為其進一步開發利用提供一定的參考。

作者簡介：

萬新煥

山東中醫藥大學碩士生導師，山東中醫藥大學“重大疾病防治中藥新藥研制與產品開發青年科研創新團隊”核心成員，主要從事藥物新制劑與新劑型研究。兼任世界中醫藥學會聯合會中醫藥抗病毒專業委員會理事，中國醫藥教育協會中醫藥教育促進工作委員會委員，山東中醫藥學會中藥制劑專業委員會委員。主持山東省自然科學基金及山東中醫藥大學青年科學基金各1項，參與省部級課題2項，廳局級課題3項；以第一作者及通訊作者在Carbohydrate Polymers、Phytomedicine、J Chromatogr B Analyt Technol Biomed Life Sci發表SCI論文10余篇，累計影響因子達50以上；參編著作2部，獲得軟件著作權2項。

⑥  題目：茯苓化學成分和藥理作用研究進展及質量標志物的預測分析

作者：鄧桃妹，陳衛東（安徽中醫藥大學）

摘要：茯苓Poria cocos是我國傳統的藥食同源中藥材，具有利水滲濕、健脾、寧心等功效，在藥品、食品及保健品中均有廣泛應用。隨著對茯苓的深入研究，其三萜類和多糖等主要化學成分、藥理作用及應用開發研究備受關注。對茯苓的化學成分、藥理作用進行系統綜述，根據質量標志物的概念，從親緣學及化學成分特有性、傳統藥效、傳統藥性、化學成分可測性、不同加工方法的影響等幾個方面對茯苓質量標志物進行預測分析，為茯苓質量評價研究和產品開發提供科學依據。

作者簡介：

陳衛東 教授

安徽中醫藥大學中藥學博士生導師。主要從事于藥物代謝動力學、藥劑學、道地中藥材品質提升與可持續發展等方面的研究工作。

中國藥理學會藥物代謝專業委員會副主任委員，中國菌物協會茯苓產業分會副會長，國家藥監局中藥質量研究與評價重點實驗室學術委員會委員。安徽省藥學會常務理事，安徽省藥學會藥物代謝專業委員會名譽主任委員。主持國家自然科學基金面上項目2項，國家科技重大專項重大新藥創制專項1項以及國家中醫藥管理局中藥標準化項目，安徽省重大專項、中央引導地方發展專項等課題共20余項。獲安徽省自然科學獎三等獎（排名第一）。在 Hepatology、Carbohydrate Polymers、DMD、APSB等期刊發表SCI收錄論文70余篇（IF >10，7篇）；在《中草藥》《中國藥學雜志》《中國中藥雜志》等中文核心期刊發表論文100余篇；授權發明專利4項；編寫著作8部；申請新品種2項；制定安徽省地方標準1項。

⑦  題目：基于源頭控制的中藥制劑質量研究

作者：陽長明，周思源（國家藥品監督管理局 藥品評審中心）

摘要：中藥制劑的研究設計、中藥材質量、飲片炮制加工以及中藥制劑生產過程控制是影響中藥制劑質量的關鍵因素，也是中藥制劑質量控制的源頭。通過對中藥制劑質量控制現狀的分析，對《中藥新藥用藥材質量控制研究技術指導原則（試行）》《中藥新藥用飲片炮制研究技術指導原則（試行）》《中藥新藥質量標準研究技術指導原則（試行）》3個指導原則主要內容的介紹和解讀，提出基于源頭控制的中藥制劑質量研究思路，即重視中藥制劑的研究設計，重視作為中藥制劑原料的中藥材質量，重視飲片炮制加工及重視制劑生產過程控制，構建符合中藥特點的質量標準體系，控制中藥制劑的質量。

作者簡介：

陽長明  博士

主任藥師，高級審評員，國家藥品監督管理局藥品審評中心中藥民族藥藥學部部長，國家藥典委員會委員，中華中醫藥學會中藥制劑分會副主任委員，曾獲衛生部有突出貢獻中青年專家、全國科技系統抗擊新冠肺炎疫情先進個人稱號。

⑧  題目：水蛭凍干粉對糖尿病腎病大鼠腎組織損傷的保護作用

作者：楊帆，陳志強（河北中醫學院）

摘要：目的 探討水蛭凍干粉對糖尿病腎病大鼠腎組織損傷的保護作用。方法 SD大鼠隨機選取8只作為對照組，其余大鼠給予高脂飼料喂養聯合ip鏈脲佐菌素（35 mg/kg）建立糖尿病腎病模型，成模大鼠隨機分為模型組及水蛭凍干粉低、中、高劑量（0.3、0.6、1.2 g/kg）組。給藥16周后，檢測大鼠24 h尿微量白蛋白（24 h urinary microalbumin，24 h-mALB）、空腹血糖、尿素氮（urea nitrogen，BUN）、肌酐（creatinine，Scr）水平和腎質量/體質量；采用TBA法和羥胺法測定大鼠血清超氧化物歧化酶（superoxide dismutase，SOD）活性和丙二醛（malondialdehyde，MDA）水平；采用ELISA法檢測大鼠血清腫瘤壞死因子-α（tumor necrosis factor-α，TNF-α）、白細胞介素-1β（interleukin-1β，IL-1β）和單核細胞趨化因子-1（monocyte chemokine-1，MCP-1）水平；Western blotting法檢測大鼠腎組織Janus蛋白酪氨酸激酶2/信號轉導和轉錄激活子1、3（janus kinase 2/signal transducer and activator of transcription1、3，JAK2/STAT1/STAT3）通路相關蛋白表達。結果 與對照組比較，模型組大鼠24 h-mALB、空腹血糖、腎功能（BUN、Scr）、腎質量/體質量指標均顯著升高（P<0.01），血清MDA、TNF-α、IL-1β和MCP-1水平顯著增加（P<0.01），SOD活性顯著降低（P<0.01），腎組織JAK2/STAT1/STAT3通路被激活（P<0.05、0.01）。與模型組比較，水蛭凍干粉組大鼠24 h-mALB排泄降低（P<0.01），腎功能（BUN、Scr）、腎質量/體質量改善（P<0.05、0.01），氧化損傷減輕（P<0.05、0.01），血清炎癥因子水平下降（P<0.05、0.01），腎組織JAK2/STAT1/STAT3通路被抑制（P<0.05、0.01）。結論 水蛭凍干粉可能通過抑制糖尿病腎病大鼠氧化應激及炎癥因子的產生，抑制腎組織JAK2/STAT1/STAT3信號通路活化，從而降低mALB排泄，改善腎功能，進而發揮腎臟保護作用。

作者簡介：

楊帆  博士

醫學博士，助理研究員，主治醫師，河北中醫藥學會腎病專業委員會委員，主要從事慢性腎臟病的中醫藥治療及其機制研究。主持和參與國家自然科學基金課題1項，河北省自然科學基金課題2項，河北省重點研發計劃項目1項，河北省教育廳課題2項，河北省中醫藥管理局課題4項，河北省衛健委課題1項，河北中醫學院博士基金課題1項，指導國家級大學生創新創業課題1項，發表SCI論文2篇，CSCD論文20余篇，科技核心2篇。

《現代藥物與臨床》1篇：

⑨  題目：抗生素耐藥與抗生素新藥開發的研究進展

作者：孫雙勇，王玉麗（天津醫藥集團研究院）

摘要：抗生素的發現和使用是20世紀最偉大的成就之一。隨著抗生素的廣泛應用，抗生素耐藥成為藥物使用時應重點關注的問題。抗生素耐藥主要與細菌的自然選擇、抗生素不合理使用有關，同時也使得抗生素新藥的開發存在著諸多挑戰。世界衛生組織（WHO）一直關注抗生素的危害和耐藥問題，認為這些問題已經成為公共衛生和可持續醫療的最嚴重挑戰。對抗生素耐藥現狀、原因、機制和抗生素新藥開發的研究進展進行綜述，為應對抗生素耐藥，需要全球醫學家、企業家、各國政府和公眾共同努力，相信一定可以找到解決抗生素耐藥的適宜途徑。

作者簡介：

孫雙勇 博士

研究員，津藥生物科技有限公司（原天津醫藥集團研究總院）創新藥研究中心藥理室負責人，天津醫科大學、天津中醫藥大學碩士生導師，主要研究方向為創新藥的設計與臨床前評價研究。近年來發表學術論文50余篇，申報專利10項，獲臨床批件9個；擔任《中國藥物評價》、《中國實驗動物學報》、《中國比較醫學雜志》雜志編委或青年編委；入選天津市特支計劃“青年拔尖人才”、天津市科技局入庫專家、天津市“創新創業創優”先進個人、天津市“131人才”等人才計劃。

《藥物評價研究》1篇：

⑩  題目：丹參有效成分及丹參類制劑抗炎藥理作用的研究進展

作者：原景，鞠愛春（天津中醫藥大學）

摘要：中藥在治療炎癥方面具有療效較好、毒副作用小等優點。綜述丹參Salvia miltiorrhiza中的水溶性成分（丹酚酸A、丹參莖葉總酚酸、丹酚酸B、迷迭香酸、丹參素等）、脂溶性成分（丹參酮IIA、丹參酮I、隱丹參酮、甲基丹參酮等）、丹參多糖，丹參類注射液（丹參注射液、注射用丹參多酚酸、丹紅注射液等）以及丹參其他類制劑（如丹參凝膠、丹參涂膜劑等）的抗炎藥理作用研究進展，以期為丹參抗炎作用研究及丹參的臨床應用提供參考。

作者簡介：

李德坤 研究員

天津天士力之驕藥業有限公司藥物警戒總監，天津市中藥注射劑安全性評價企業重點實驗室執行主任。2001年入職天士力集團，從事中藥工藝開發、質量及標準研究、藥效及安全性研究、藥物警戒研究等。研究成果獲得天津科技進步一等獎2項、北京科技進步一等獎1項、天津科技進步二等獎2項、協會獎項4項。發表文章186篇，20項發明專利獲得授權。中國中藥協會中藥產品開發與培育專委會常委、中華中醫藥學會中藥毒理學與安全性研究分會常委、《藥物評價研究》編委。